top of page
Texture_linecircles.png
ABOUT US
abstract.png

Deverra Therapeutics, Inc. is a clinical stage biotechnology company located in Seattle, Washington, developing allogeneic, off-the-shelf universal donor cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. 

Lab4a.jpg

NOW LIVE! Deverra’s equity crowdfunding campaign is live on StartEngine!

​

The company has exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and multiple clinical trials.

 

Our innovative and well-established platform can be used to generate a range of unmodified and modified (engineered) progenitor and immune cells to boost the patient’s blood and immune system to eliminate cancer and virally infected cells.

 

Deverra’s team includes pioneers who were the first to demonstrate clinical effectiveness using expanded stem cell therapies and  non-HLA matched, off-the-shelf universal donor cell therapies.

placeholder1.jpg
Video_still.jpg

OUR PARTNERS

ResearchPartners_FredHutch.png
ResearchPartners_Coeptis.png
ResearchPartners_TwinStrand.png
ResearchPartners_NYBB.png

Research Partners

Cord Blood Bank Partners

ResearchPartners_NCBP.png
ResearchPartners_CCB.png
bottom of page